CA
ZNTL icon

Cliff Asness’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Cliff Asness’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,675
Closed -$53.1K – 3975
2026
Q1 		$53.1K Sell
22,675
-23,320
-51% -$60.2K ﹤0.01% 3711
2025
Q4 		$62.1K Sell
45,995
-60,970
-57% -$88.7K ﹤0.01% 3500
2025
Q3 		$162K Sell
106,965
-327,993
-75% -$492K ﹤0.01% 3302
2025
Q2 		$505K Sell
434,958
-184,372
-30% -$243K ﹤0.01% 2609
2025
Q1 		$985K Buy
619,330
+396,233
+178% +$854K ﹤0.01% 2022
2024
Q4 		$676K Buy
223,097
+27,615
+14% +$90.5K ﹤0.01% 2097
2024
Q3 		$719K Buy
+195,482
New +$710K ﹤0.01% 2010
2022
Q2 		– Sell
-4,517
Closed -$208K – 2313
2022
Q1 		$208K Sell
4,517
-2,725
-38% -$147K ﹤0.01% 2052
2021
Q4 		$609K Buy
+7,242
New +$560K ﹤0.01% 1765

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Cliff Asness's ZNTL Position: Q2 2026 in Review

Cliff Asness sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 22,675 shares — an estimated $53.1K sold.

Cliff Asness first reported a position in ZNTL in Q4 2021 and held it in 9 quarters. The position peaked at $985K in Q1 2025. 113 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Cliff Asness reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Cliff Asness sold 22,675 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $53.1K.
  • Cliff Asness first reported a position in Zentalis Pharmaceuticals in Q4 2021 and held it in 9 quarters.
  • Cliff Asness's Zentalis Pharmaceuticals position peaked at $985K in Q1 2025.
  • 113 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.